Clinical Effect of Etidronate on Alveolar Pyorrhoea Associated with Chronic Marginal Periodontitis: Report of Four Cases

Takaishi, Yoshitomo; Miki, Takami; Nishizawà, Yoshiki; Morii, Hirotoshi

doi:10.1177/147323000102900413

Cited by 12 publications

(11 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some patients in our study took risedronate or alendronate, which are bisphosphonates, which may improve periodontal health but also may cause osteonecrosis and painful refractory bone exposures of the jaws. 26-31 The incidence of osteonecrosis of the jaw in patients taking oral bisphosphonate therapy for osteoporosis is low, with a reported risk of less than 1 in 100,000 patients. 32 Some of the patients in our study took estrogen, which may benefit periodontal health.…”

Section: Discussionmentioning

confidence: 99%

Calcium and vitamin D use among adults in periodontal disease maintenance programmes

et al. 2009

View full text Add to dashboard Cite

Objectives Determine the level of calcium and vitamin D oral supplementation in patients in periodontal disease maintenance programs. Design Convenience survey. Setting St. Louis Metropolitan region. Subjects and Methods Patients (n=228) in two university-based, periodontal-disease maintenance programs. Main Outcome Measures Reported amounts of oral calcium and vitamin D supplementation were tested for differences based on gender and race. Results The last published recommended daily intakes from the United States (U.S.) Food and Nutrition Board (FNB) for adults >50 years of age are 1200 mg calcium and 400 IU vitamin D (or 600 IU if over 70). The mean age of the 228 patients (125 females and 103 males) was 63.6±11.0 years (standard deviation). Of the 228 patients surveyed: (1) 204(89%) were >50 years of age, and of these, only 15(7%) met the U.S. FNB’s recommended intakes of calcium and vitamin D from supplementation, (2) 138(66%) reported that they took no oral supplementation, with significantly more males (n=82) than females (n=56) not taking supplementation (p=0.03), (3) 88(39%) took calcium supplementation, with females (947±511mg/day) taking significantly (p<0.001) more than males (632±907mg/day), and (4) 66(29%) took vitamin D supplementation, with females(420±227 IU/day) taking approximately the same amount as males (443±317 IU/day, p>0.05). The amounts of oral supplementation did not vary with race (p>0.05). Conclusion The use of calcium and vitamin D supplementation has been promoted for years; yet the numbers of adults taking supplements remains low and the level of supplementation varies greatly. Knowledge of the benefits of supplementation needs to be better disseminated and research needs to be conducted to determine optimal levels of calcium and vitamin D supplementation.

show abstract

Section: Discussionmentioning

confidence: 99%

Calcium and vitamin D use among adults in periodontal disease maintenance programmes

et al. 2009

View full text Add to dashboard Cite

show abstract

“…We have previously reported the effects of intermittent cyclical etidronate (ICE) administered to four patients with periodontal disease for 2 -3 years in addition to ordinary dental treatment for periodontitis. 1 This present study describes the results of following these same patients for an additional 2 -3 years.…”

Section: Introductionmentioning

confidence: 87%

Suppression of Alveolar Bone Resorption by Etidronate Treatment for Periodontal Disease: 4- to 5-Year Follow-up of Four Patients

Takaishi¹,

Ikeo

Miki

et al. 2003

J Int Med Res

Self Cite

View full text Add to dashboard Cite

Four women with periodontitis received intermittent cyclical etidronate (etidronate administered orally at a dose of 200 mg/day for 2 weeks, at intervals of 10-12 weeks or 6 months) for 4-5 years in addition to ordinary dental therapy. Alveolar bone density was measured using a new method comparing the percentage increase in density. Mean alveolar bone density increased significantly during intermittent cyclical etidronate treatment. Significant reductions were observed in the mobility of the teeth and the depth of periodontal pockets. There were significant correlations between alveolar bone density and both mobility of the teeth and the depth of the alveolar pockets. It is concluded that increases in alveolar bone density are associated with the clinical benefits of etidronate in the treatment of periodontitis.

show abstract

“…Similarly, the level of NTX ⁄ creatine, a marker for bone resorption, had statistically significantly improved in the alendronate group at the end of the study. The case series reported by Takaishi et al (149) indicated that there was a clinical and radiographic improvement when a bisphosphonate was combined with conventional periodontal treatment.…”

Section: Role Of Bone-sparing Agentsmentioning

confidence: 99%

“…The case series reported by Takaishi et al. (149) indicated that there was a clinical and radiographic improvement when a bisphosphonate was combined with conventional periodontal treatment.…”

Section: Periodontal Management Of Osteopenia Patientsmentioning

confidence: 99%

Decreased bone mineral density and periodontal management

Reddy¹,

Morgan²

2012

Periodontology 2000

View full text Add to dashboard Cite

The definition of osteoporosis has evolved beyond low bone mineral density to include impaired bone morphology and matrix properties. As such, the subsequent bone density insufficiencies extend beyond the skeletal risks of fracture and have implications for oral health management patients. As our population ages there is a worldwide increase in the risk of decreased bone mineral density and its subsequent morbidity. This makes age an independent risk factor for fracture and decreased bone mineral density. Multiple examinations and diagnostic tests are currently used in combination to develop an algorithm to assess osteoporotic risk. Oral health care professionals should follow these principles and caution should be used in applying a single independent assessment to determine a patient's osteoporotic or bone metabolism risk. Therapeutic approaches for osteoporosis are often divided into nonpharmacological interventions and pharmacological therapies. The periodontist and other oral health care professionals should have a full understanding of the therapeutic options, benefits and implementation of preventive therapies. Bone turnover is a coupled event of bone formation and bone resorption and it is the imbalance of this homeostasis that results in osteoporosis. Based on this uncoupling of bone resorption and formation, osteoporosis or decreased bone mineral density and osteopenia, may be a risk factor for alveolar bone loss in periodontitis. The role of prevention and maintenance with a history of periodontitis and oesteopenia extends beyond biofilm control and should include management of bone mineral density. The chronic periodontal infection in a patient with osteopenia may place the patient at greatly increased risk for alveolar bone loss, gingival recession and root caries. A key component in the management is the oral health professional's knowledge of the interrelationship between skeletal health and periodontal health.

show abstract

Clinical Effect of Etidronate on Alveolar Pyorrhoea Associated with Chronic Marginal Periodontitis: Report of Four Cases

Cited by 12 publications

References 13 publications

Calcium and vitamin D use among adults in periodontal disease maintenance programmes

Calcium and vitamin D use among adults in periodontal disease maintenance programmes

Suppression of Alveolar Bone Resorption by Etidronate Treatment for Periodontal Disease: 4- to 5-Year Follow-up of Four Patients

Decreased bone mineral density and periodontal management

Contact Info

Product

Resources

About